Advanced Biomed Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026, reporting financial results for the first fiscal quarter of its 2027 fiscal year.

Key Highlights

  • Net loss of $989,054 for the three months ended September 30, 2026, compared to a net loss of $386,901 for the same period in 2025, according to the filing.
  • No revenue reported for the three months ended September 30, 2026 or the comparable prior-year period.
  • General and administrative expenses rose to $973,931 for the quarter, up from $147,155 in the three months ended September 30, 2025.
  • Total assets of $12,902,648 as of September 30, 2026, down from $13,750,716 as of June 30, 2026.
  • Accumulated deficit of $13,545,021 as of September 30, 2026, compared to $12,555,967 as of June 30, 2026.
  • 1,652,133 shares of common stock issued and outstanding as of September 30, 2026, reflecting a 1-for-20 reverse stock split effected on February 20, 2026.
  • Loss per share of $(0.60) from continuing operations, basic and diluted, for the three months ended September 30, 2026.

Advanced Biomed's Financial Results for the Quarter Ended September 30, 2026

Advanced Biomed Inc. (NASDAQ:ADVB), a Nevada-incorporated company headquartered in Tsuen Wan, New Territories, Hong Kong, reported a net loss of $989,054 for the three months ended September 30, 2026, according to its quarterly filing. This compares to a net loss of $386,901 for the same period in 2025, which included a $239,746 loss from discontinued operations. The company disclosed no revenue in either period.

The filing shows that general and administrative expenses were the sole operating cost for the quarter, totaling $973,931, a significant increase from $147,155 in the prior-year quarter. The company also reported interest expense of $15,123 for the three months ended September 30, 2026, resulting in a loss before income tax expense of $989,054. Income tax expense was reported as zero for both periods. Loss per share from continuing operations, basic and diluted, was $(0.60) for the quarter, compared to $(0.14) in the year-ago period, with the weighted average shares outstanding at 1,652,133 versus 1,082,000, both figures giving retroactive effect to the 1-for-20 reverse stock split effected on February 20, 2026.

The condensed consolidated balance sheet as of September 30, 2026 showed total assets of $12,902,648, with cash of $213,995 and prepaid expenses and other current assets of $12,653,953 making up the bulk of current assets. Total liabilities stood at $1,614,873, including a new lease payable reflecting right-of-use assets of $33,496 that were not present as of June 30, 2026. Total stockholders' equity was $11,287,775 as of September 30, 2026, down from $12,276,727 as of June 30, 2026. The company's annual report on Form 10-K was filed with the SEC on October 13, 2026, as referenced in the filing. Forward-looking statements in the filing are the company's own and are subject to its cautionary language.

What Was Disclosed

Advanced Biomed Inc. disclosed its unaudited condensed consolidated financial results for the quarter ended September 30, 2026, reporting zero revenue, a net loss of $989,054, total assets of $12,902,648, and an accumulated deficit of $13,545,021, with 1,652,133 shares outstanding.